Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02850016 · ClinicalTrials.gov registry record · Phase 2
Romidepsin Plus 3BNC117 Phase 2a Study
A Phase 2 study of Human Immunodeficiency Virus (HIV), sponsored by Rockefeller University.
- Completed
- Registry status
- Phase 2
- Development phase
- 48
- Enrollment target
- 3
- Study locations
NCT02850016: Completed Phase 2 study of Human Immunodeficiency Virus (HIV), sponsored by Rockefeller University.
NCT02850016 is a Phase 2 study of Human Immunodeficiency Virus (HIV) that has completed, run by Rockefeller University. The registered enrollment target is 48 participants, below the 506-participant average among 18 other Human Immunodeficiency Virus (HIV) trials with a reported enrollment target (91% lower). The trial reports 3 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02850016, a Phase 2 study of Human Immunodeficiency Virus (HIV), has completed, sponsored by Rockefeller University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 48 participants
- Enrollment target
- 3
- Study locations
Study Summary
The aim of this protocol is to evaluate the effects of romidepsin plus 3BNC117 or romidepsin alone on delaying or preventing viral rebound in ART-treated HIV-1-infected individuals during an analytical interruption of ART.
Primary Outcome
Viral rebound is defined as HIV-1 RNA ≥ 200 copies/mL on 2 consecutive measurements during ATI. If viral rebound occurs, the date of the first measurement of HIV-1 RNA ≥ 200 copies/mL will be defined as "date of viral rebound
Conditions Studied
Interventions
- DRUG Romidepsin
- DRUG 3BNC117
Study Locations (3)
Other
- Aarhus University Hospital - Aarhus
- University of Cologne - Cologne
New York
- The Rockefeller University - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2017-01-06 |
| Est. Completion | 2020-12-31 |
| Phase | Phase 2 |
What the finished NCT02850016 record still lists
NCT02850016 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 48 participants, a relatively small participant target, below the 506-participant average among 18 other Human Immunodeficiency Virus (HIV) trials with a reported enrollment target (91% lower).
The record links to 1 condition, with Human Immunodeficiency Virus (HIV) appearing as the primary indexed condition, and to 2 interventions - of which Romidepsin is the first listed.
NCT02850016 reports a single indexed study location in Other, New York.
Frequently Asked Questions
What is clinical trial NCT02850016 about?
NCT02850016 is a clinical study titled "Romidepsin Plus 3BNC117 Phase 2a Study". The aim of this protocol is to evaluate the effects of romidepsin plus 3BNC117 or romidepsin alone on delaying or preventing viral rebound in ART-treated HIV-1-infected individuals during an analytical interruption of ART.
What is the current status of trial NCT02850016?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 48 participants. The study started on 2017-01-06. Estimated completion is 2020-12-31.
What conditions does trial NCT02850016 study?
This clinical trial studies the following conditions: Human Immunodeficiency Virus (HIV).
What interventions are being tested in trial NCT02850016?
The interventions under investigation include: Romidepsin (DRUG), 3BNC117 (DRUG).
Who is sponsoring clinical trial NCT02850016?
This trial is sponsored by Rockefeller University, which has 117 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02850016 being conducted?
This trial has 3 study locations across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Human Immunodeficiency Virus (HIV)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02850016's enrollment target sits among peer trials
48 15th of 18 higher than 4 of 18 other Human Immunodeficiency Virus (HIV) trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Human Immunodeficiency Virus (HIV) trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Phase II Safety and Acceptability of an Investigational Injectable Product, TMC278LA, for Pre-Exposure Prophylaxis
COMPLETED · Phase 2
-
Persuasive Health Communication Intervention for HIV/HCV
RECRUITING · NA
-
Quitting Matters Human Immunodeficiency Virus Hybrid Trial
RECRUITING · NA
-
A Clinical Study of MK-8527 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-011)
RECRUITING · Phase 3
-
The Trans-Led Care Study
RECRUITING · NA
-
Project neuroARTEMIS
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01765777 · 48 participants · NA
Efficacy of Osteopathic Manipulative Medicine (OMM) and Phototherapy for Patients With Chronic Lower Back Pain
- NCT03073343 · 48 participants · NA
A Prospective, Randomized, Open Label Trial of Two Doses of Oral Betaine
- NCT03431064 · 48 participants
Lung Recruitment Maneuver as a Potential Predictor of Fluid Responsiveness in Mechanically Ventilated Pediatric Patients
- NCT03514602 · 48 participants · NA
Maternal Smoking Cessation and Pediatric Obesity Prevention
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI